|Application ||WB, IHC|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||44971 Da|
|Homology||Rat, human and canis ג€“ identical.|
|Other Names||Adenosine receptor A2a, Adora2a|
|Related products for control experiments||Control peptide antigen (supplied with the antibody free of charge).|
|Target/Specificity||Peptide (C)RQLKQMESQPLPGER, corresponding to amino acid residues 201-215 of mouse A2A Adenosine receptor (Accession Q60613). 3rd intracellular loop.|
|Peptide Confirmation||Confirmed by amino acid analysis.|
|Format||Affinity purified antibody, lyophilized powder|
|Reconstitution||50 µl or 0.2 ml deionized water, depending on the sample size.|
|Antibody Concentration After Reconstitution||0.75 mg/ml.|
|Buffer After Reconstitution||Phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.05% NaN3.|
|Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Storage After Reconstitution||The reconstituted solution can be stored at 4ºC for up to 2 weeks. For longer periods, small aliquots should be stored at -20ºC or below. Avoid multiple freezing and thawing. The further dilutions should be made using a carrier protein such as BSA (1%). Centrifuge all antibody preparations before use (10000 × g 5 min).|
|Control Antigen Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Control Antigen Reconstitution||100 µl water.|
|Control Antigen Storage After Reconstitution||-20ºC.|
|Preadsorption Control||1 µg peptide per 1 µg antibody.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Adenosine is an endogenous nucleoside generated locally in tissues under conditions of hypoxia, ischemia, or inflammation. It modulates a variety of physiological functions of many tissues including brain and heart.1,2 Adenosine exerts its action via four specific adenosine receptors (also named P1 purinergic receptors): A1-Adenosine Receptor (A1AR), A2A-Adenosine Receptor (A2AAR), A2B-Adenosine Receptor (A2BAR), and A3-Adenosine Receptor (A3AR). All are integral membrane proteins and are members of the G protein-coupled receptor superfamily, which share a common structure of seven putative transmembrane domains, an extracellular NH2 terminus, cytoplasmic COOH terminus, and a third intracellular loop important for binding G proteins.1-3 The adenosine receptors can be distinguished on the basis of their differential selectivity for adenosine analogs.1-3 Adenosine receptors control neurotransmitter release through the facilitatory A2AAR and the inhibitory A1AR.4 A2AAR and A1AR are the major adenosine receptor subtypes expressed in the central nervous system (CNS). A2AAR is mainly expressed in the striatum on GABAergic striatopallidal neurons, while A1AR is widely distributed throughout the CNS.5,6 A2AAR was suggested to play a critical role in attenuation of systemic inflammatory responses and prevention of extensive tissue damage.7 It was suggested that extracellular adenosine that accumulates in inflamed and damaged tissue may activate the A2AAR expressed in immune cells leading to termination/inhibition of the immune response.7 It was further suggested that this same mechanism may protect tumors from antitumor T cells through an immunosuppressive signal generated by the activation of A2AAR on T cells by extracellular adenosine produced from hypoxic cancerous tissues.8 Abgent is pleased to introduce a new antibody directed against an epitope of mouse A2A-Adenosine receptor. Anti-A2A Adenosine Receptor antibody (#AG1386) can be used in western blot and immunohistochemical applications, and has been designed to recognize A2AAR from human, rat, and mouse samples.
1. Okusa, M.D. (2002) Am. J. Physiol. Renal. Physiol. 282, F10.
2. Fredholm, B.B. et al. (2001) Pharmacol. Rev. 53, 527.
3. Nakata, H. (1989) J. Biol. Chem. 264, 16545.
4. Cunha, R.A. (2001) Neurochem. Int. 38, 107.
5. Fredholm, B.B. et al. (2000) Naunyn-Schmiedebergs Arch. Pharmacol. 362, 364.
6. Canals, M. et al. (2005) J. Neurochem. 92, 337.
7. Ohta, A. and Sitkovsky, M. (2001) Nature 414, 916.
8. Ohta, A. et al. (2006) Proc. Natl. Acad. Sci. 103, 13132.
If you have any additional inquiries please email technical services at email@example.com.